Pharmacokinetics and Dosimetry of 177 Lu-DOTATATE in Patients with Advanced Well-Differentiated, Gastroenteropancreatic Neuroendocrine Tumors: Results from a Substudy of the Phase 3 XT-XTR008-3-01 Trial
Molecular Pharmaceutics · 06.07.2026 · 23 (7) · 3688-3696
DOI: 10.1021/acs.molpharmaceut.6c00126 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Molecular Pharmaceutics, online erschienen am 05.06.2026. Verfasst von Guangyu Ma und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The First Medical Center, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, China. Hauptthemen laut MEDLINE: Intestinal Neoplasms, Neuroendocrine Tumors, Octreotide, Organometallic Compounds. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Sinotau Pharmaceutical Group.
Abstract (Originalsprache)
This substudy presents the exploratory pharmacokinetic (PK) and dosimetry profile of XTR008, 177Lu-DOTATATE developed in China, from the phase 3 trial XT-XTR008-3-01. 10 patients with well-differentiated, locally advanced, or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) received 4 cycles of 177Lu-DOTATATE (7.4 GBq/cycle). Postfirst dose, whole-body planar scintigraphy (up to 7 days), abdominal SPECT/CT (24/48 h), and blood and urine sampling for PK, safety, and efficacy assessment were performed. 177Lu-DOTATATE peaked in blood at 15 min, then decreased with a T1/2 of 37.36 ± 16.44 h. 60.38% was excreted in urine within 16 h. For four cycles, the mean absorbed doses to kidneys and red marrow were 18.914 ± 6.242 Gy (excluding one patient with nephrolithiasis and absorbed dose to kidneys of 77.1Gy) and 1.199 ± 0.337 Gy, respectively. Two patients had absorbed doses to the kidneys higher than 23 Gy (25.9 Gy, 23.1 Gy) without renal toxicity. Hematological toxicities (mostly grade 1/2) were the most common treatment-related adverse events (TRAEs). No significant association was found between organ doses and specific toxicities. Tumor absorbed dose varied widely (0.312-9.78 Gy/GBq). An objective response rate (ORR) was 30% (3/10); tumor dose did not significantly differ between responders (2.68 ± 2.53 Gy/GBq) and nonresponders (2.93 ± 1.81 Gy/GBq, p = 0.44). Tumor dose correlated moderately but nonsignificantly with size change (r = 0.016, p > 0.05). PRRT with XTR008 showed favorable tolerability, PK, and dosimetry in patients with advanced GEP-NETs, supporting its use in Chinese patients with well-differentiated GEP-NETs as a new treatment option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, The First Medical Center, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, China.
- Beijing Sinotau Intl. Pharmaceutical Technology Co., Ltd., 8 Zhongguancun Life Science Park, Changping District, Beijing 102206, China.
ORCID-Profile: Guangyu Ma
Förderung
- Sinotau Pharmaceutical Group
Zitieren
APA
Ma, G., Dong, Y., Sun, S., Wang, Y., Ji, H., Xu, X., Yang, Q., Sun, Y., Zhou, H., Zhang, X., Ye, T., Yin, A., & Wang, R. (2026). Pharmacokinetics and Dosimetry of 177 Lu-DOTATATE in Patients with Advanced Well-Differentiated, Gastroenteropancreatic Neuroendocrine Tumors: Results from a Substudy of the Phase 3 XT-XTR008-3-01 Trial. Molecular Pharmaceutics, 23(7), 3688-3696. https://doi.org/10.1021/acs.molpharmaceut.6c00126
Vancouver
Ma G, Dong Y, Sun S, Wang Y, Ji H, Xu X, et al. Pharmacokinetics and Dosimetry of 177 Lu-DOTATATE in Patients with Advanced Well-Differentiated, Gastroenteropancreatic Neuroendocrine Tumors: Results from a Substudy of the Phase 3 XT-XTR008-3-01 Trial. Molecular Pharmaceutics. 2026;23(7):3688-3696. doi:10.1021/acs.molpharmaceut.6c00126
BibTeX
@article{Ma2026,
author = {Ma, Guangyu and Dong, Yanliang and Sun, Shuwei and Wang, Yuan and Ji, Huijuan and Xu, Xiaodan and Yang, Qiaoying and Sun, Yabing and Zhou, Hui and Zhang, Xiaojun and Ye, Ting and Yin, Ang and Wang, Ruimin},
title = {Pharmacokinetics and Dosimetry of 177 Lu-DOTATATE in Patients with Advanced Well-Differentiated, Gastroenteropancreatic Neuroendocrine Tumors: Results from a Substudy of the Phase 3 XT-XTR008-3-01 Trial},
journal = {Molecular Pharmaceutics},
year = {2026},
volume = {23},
number = {7},
pages = {3688--3696},
doi = {10.1021/acs.molpharmaceut.6c00126}
}
EUVIMED